Management of side effects of immune checkpoint blockade by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanoma

JDDG - Journal of the German Society of Dermatology

Volumn 14, Issue 7, 2016, Pages 662-681

  Kähler, Katharina C ^a   Hassel, Jessica C ^b   Heinzerling, Lucie ^c   Loquai, Carmen ^d   Mössner, Rotraut ^e   Ugurel, Selma ^f   Zimmer, Lisa ^f   Gutzmer, Ralf ^g  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^d JOHANNES GUTENBERG UNIVERSITY   (Germany)

^e UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^f UNIVERSITY HOSPITAL ESSEN   (Germany)

^g Hochschule   (Germany)

Author keywords

autoimmune side effects; CTLA 4 antibody; immune checkpoint blockade; melanoma; PD 1 antibody; side effect management

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; C REACTIVE PROTEIN; CALCIUM; CALGRANULIN; CREATININE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; GAMMA GLUTAMYLTRANSFERASE; HYDROCORTISONE; IPILIMUMAB; LACTATE DEHYDROGENASE; NIVOLUMAB; PEMBROLIZUMAB; POTASSIUM; PROGRAMMED DEATH 1 RECEPTOR; SODIUM; THYROTROPIN; UREA; ANTINEOPLASTIC AGENT; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; MONOCLONAL ANTIBODY;

ADVERSE DRUG REACTION; ARTHRALGIA; ARTICLE; BLOOD ANALYSIS; BLOOD CELL COUNT; CANCER IMMUNOTHERAPY; CARDIOMYOPATHY; CHECKLIST; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); COLITIS; CYTOKINE RELEASE SYNDROME; DERMATOMYOSITIS; DIABETIC KETOACIDOSIS; DIARRHEA; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG ERUPTION; DRUG MECHANISM; ENDOCRINE OPHTHALMOPATHY; EPISCLERITIS; FATIGUE; GIANT CELL ARTERITIS; HEMATOLOGIC DISEASE; HEPATITIS; HUMAN; HYPOPHYSITIS; HYPOTHYROIDISM; IMMUNE RESPONSE; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY DISEASE; LIVER TOXICITY; LUNG DISEASE; MACULOPAPULAR RASH; MANAGED CARE; MEDICAL HISTORY; META ANALYSIS (TOPIC); METASTATIC MELANOMA; MUCOSA; NEUROLOGIC DISEASE; PANCREAS DISEASE; PNEUMONIA; PRURITUS; RASH; RHEUMATIC POLYMYALGIA; SIDE EFFECT; SUBRETINAL NEOVASCULARIZATION; T LYMPHOCYTE; TREATMENT DURATION; UVEITIS; VASCULITIS; VITILIGO; ANTAGONISTS AND INHIBITORS; MELANOMA; SKIN TUMOR;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CTLA-4 ANTIGEN; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; IPILIMUMAB; MELANOMA; SKIN NEOPLASMS;

EID: 84978128155     PISSN: 16100379     EISSN: 16100387     Source Type: Journal    
DOI: 10.1111/ddg.13047     Document Type: Article

References (71)

1. Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity 2013; 39: 1–10.
2. Bertrand A, Kostine M, Barnetche T et al. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Med 2015; 13: 211.
3. Larkin J, Chiarion-Sileni V, Gonzalez R et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med 2015; 373: 23–34.
4. Faje A. Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights. Pituitary 2016; 19(1): 82–92.
5. Brahmer J, Reckamp KL, Baas P et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med 2015; 373: 123–35.
6. Nishino M, Sholl LM, Hodi FS et al. Anti-PD-1-Related Pneumonitis during Cancer Immunotherapy. N Engl J Med 2015; 373: 288–90.
7. Robert C, Schachter J, Long GV et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015; 372: 2521–32.
8. Kahler KC, Hauschild A. Treatment and side effect management of CTLA-4 antibody therapy in metastatic melanoma. J Dtsch Dermatol Ges 2011; 9: 277–86.
9. Dick J, Enk A, Hassel JC. Long-lasting responses under treatment with ipilimumab: an argument against maintenance therapy? Dermatology 2015; 230: 8–10.
10. Abdel-Rahman O, ElHalawani H, Fouad M. Risk of cutaneous toxicities in patients with solid tumors treated with immune checkpoint inhibitors: a meta-analysis. Future Oncol 2015; 11: 2471–84.
11. Ribas A, Puzanov I, Dummer R et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol 2015; 16: 908–18.
12. Gupta A, DeFelice KM, Loftus EV, Jr., Khanna S. Systematic review: colitis associated with anti-CTLA-4 therapy. Aliment Pharmacol Ther 2015; 42: 406–17.
13. Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 19-8-2010">19-8- 2010; 363: 711–23.
14. Wolchok JD, Neyns B, Linette G et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 2010; 11: 155–64.
15. Goethals L, Wilgenhof S, DeGeeter F et al. 18F-FDG PET/CT imaging of an anti-CTLA-4 antibody-associated autoimmune pancolitis. Eur J Nucl Med Mol Imaging 2011; 38: 1390–1.
16. Gupta A, Khanna S. Ipilimumab-associated colitis or refractory Clostridium difficile infection? BMJ Case Rep 2015; 2015: pii: bcr2015211160.
17. Tarhini AA, Zahoor H, Lin Y et al. Baseline circulating IL-17 predicts toxicity while TGF-beta1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma. J Immunother Cancer 2015; 3: 39.
18. Quirk SK, Shure AK, Agrawal DK. Immune-mediated adverse events of anticytotoxic T lymphocyte-associated antigen 4 antibody therapy in metastatic melanoma. Transl Res 2015; 166: 412–24.
19. Robert C, Long GV, Brady B et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015; 372: 320–30.
20. Weber JS, D'Angelo SP, Minor D et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2015; 16: 375–84.
21. Weber JS, Yang JC, Atkins MB, Disis ML. Toxicities of Immunotherapy for the Practitioner. J Clin Oncol 2015; 33: 2092–9.
22. Johncilla M, Misdraji J, Pratt DS et al. Ipilimumab-associated Hepatitis: Clinicopathologic Characterization in a Series of 11 Cases. Am J Surg Pathol 2015; 39: 1075–84.
23. Kim KW, Ramaiya NH, Krajewski KM et al. Ipilimumab associated hepatitis: imaging and clinicopathologic findings. Invest New Drugs 2013; 31: 1071–7.
24. Voskens CJ, Goldinger SM, Loquai C et al. The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS.One 2013; 8: e53745.
25. Uslu U, Agaimy A, Hundorfean G et al. Autoimmune colitis and subsequent CMV-induced hepatitis after treatment with ipilimumab. J Immunother 2015; 38: 212–5.
26. Horvat TZ, Adel NG, Dang TO et al. Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center. J Clin Oncol 2015; 33: 3193–8.
27. Eggermont AM, Chiarion-Sileni V, Grob JJ et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol 2015; 16: 522–30.
28. Min L, Hodi FS, Giobbie-Hurder A et al. Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study. Clin Cancer Res 2015; 21: 749–55.
29. Ryder M, Callahan M, Postow MA et al. Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. Endocr Relat Cancer 2014; 21: 371–81.
30. Albarel F, Gaudy C, Castinetti F et al. Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma. Eur J Endocrinol 2015; 172: 195–204.
31. Fischli S, Allelein S, Zander T, Henzen C. Endocrinologic side effects of oncologic treatment with anti-CTLA-4-antibodies. Dtsch Med Wochenschr 2014; 139: 996-1000.
32. Iwama S, DeRemigis A, Callahan MK et al. Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody. Sci Transl Med 2014; 6: 230ra45.
33. Lammert A, Schneider HJ, Bergmann T et al. Hypophysitis caused by ipilimumab in cancer patients: hormone replacement or immunosuppressive therapy. Exp Clin Endocrinol Diabetes 2013; 121: 581–7.
34. Della Vittoria SG, Fusciello C, Perri F et al. Ipilimumab in the treatment of metastatic melanoma: management of adverse events. Onco Targets Ther 2014; 7: 203–9.
35. Papavasileiou E, Prasad S, Freitag SK et al. Ipilimumab-induced Ocular and Orbital Inflammation-A Case Series and Review of the Literature. Ocul Immunol Inflamm 2015; 1–7.
36. Borodic G, Hinkle DM, Cia Y. Drug-induced Graves disease from CTLA-4 receptor suppression. Ophthal Plast Reconstr Surg 2011; 27: e87–e88.
37. McElnea E, Ni MA, Moran S et al. Thyroid-like ophthalmopathy in a euthyroid patient receiving Ipilimumab. Orbit 2014; 33: 424–7.
38. Min L, Vaidya A, Becker C. Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy. Eur J Endocrinol 2011; 164: 303–7.
39. Mantopoulos D, Kendra KL, Letson AD, Cebulla CM. Bilateral Choroidopathy and Serous Retinal Detachments During Ipilimumab Treatment for Cutaneous Melanoma. JAMA Ophthalmol 2015; 133: 965–7.
40. Modjtahedi BS, Maibach H, Park S. Multifocal bilateral choroidal neovascularization in a patient on ipilimumab for metastatic melanoma. Cutan Ocul Toxicol 2013; 32: 341–3.
41. Crosson JN, Laird PW, Debiec M et al. Vogt-Koyanagi-Harada-like syndrome after CTLA-4 inhibition with ipilimumab for metastatic melanoma. J Immunother 2015; 38: 80–4.
42. Wong RK, Lee JK, Huang JJ. Bilateral drug (ipilimumab)-induced vitritis, choroiditis, and serous retinal detachments suggestive of vogt-koyanagi-harada syndrome. Retin Cases Brief Rep 2012; 6: 423–6.
43. Goldstein BL, Gedmintas L, Todd DJ. Drug-associated polymyalgia rheumatica/giant cell arteritis occurring in two patients after treatment with ipilimumab, an antagonist of ctla-4. Arthritis Rheumatol 2014; 66: 768–9.
44. Liao B, Shroff S, Kamiya-Matsuoka C, Tummala S. Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma. Neuro Oncol 2014; 16: 589–3.
45. Attia P, Phan GQ, Maker AV, Robinson MR et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 2005; 23: 6043–53.
46. Topalian SL, Sznol M, McDermott DF et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014; 32: 1020–30.
47. Gettinger SN, Horn L, Gandhi L et al. Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer. J Clin Oncol 2015; 33: 2004–12.
48. Di Giacomo AM, Biagioli M, Maio M. The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications. Semin Oncol 2010; 37: 499–507.
49. Izzedine H, Gueutin V, Gharbi C et al. Kidney injuries related to ipilimumab. Invest New Drugs 2014; 32: 769–73.
50. Thajudeen B, Madhrira M, Bracamonte E, Cranmer LD. Ipilimumab granulomatous interstitial nephritis. Am J Ther 2015; 22: e84–e87.
51. Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366: 2443–54.
52. Robert C, Ribas A, Wolchok JD et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 2014; 384: 1109–17.
53. Postow MA, Chesney J, Pavlick AC et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 2015; 372: 2006–17.
54. Tarhini A. Immune-mediated adverse events associated with ipilimumab CTLA-4 blockade therapy: the underlying mechanisms and clinical management. Scientifica. (Cairo). 2013; 2013: 857519.
55. Thaipisuttikul I, Chapman P, Avila EK. Peripheral neuropathy associated with ipilimumab: a report of 2 cases. J Immunother 2015; 38: 77–9.
56. Johnson DB, Saranga-Perry V, Lavin PJ et al. Myasthenia Gravis Induced by Ipilimumab in Patients With Metastatic Melanoma. J Clin Oncol 2015; 33(33): e122–4.
57. Yang JC, Hughes M, Kammula U et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother 2007; 30: 825–30.
58. Abdallah AO, Herlopian A, Ravilla R et al. Ipilimumab-induced necrotic myelopathy in a patient with metastatic melanoma: A case report and review of literature. J Oncol Pharm Pract 2015 Feb 23. pii: 1078155215572932. [Epub ahead of print].
59. Murphy KP, Kennedy MP, Barry JE et al. New-onset mediastinal and central nervous system sarcoidosis in a patient with metastatic melanoma undergoing CTLA4 monoclonal antibody treatment. Oncol Res Treat 2014; 37: 351–3.
60. O'Day SJ, Maio M, Chiarion-Sileni V et al. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann Oncol 2010; 21: 1712–7.
61. Mandel JJ, Olar A, Aldape KD, Tremont-Lukats IW. Lambrolizumab induced central nervous system (CNS) toxicity. J Neurol Sci 2014; 344: 229–31.
62. O'Kane GM, Lyons TG, Colleran GC et al. Late-onset paraplegia after complete response to two cycles of ipilimumab for metastatic melanoma. Oncol Res Treat 2014; 37: 757-60.
63. Delyon J, Mateus C, Lambert T. Hemophilia A induced by ipilimumab. N Engl J Med 2011; 365: 1747–8.
64. Geisler BP, Raad RA, Esaian D et al. Apical ballooning and cardiomyopathy in a melanoma patient treated with ipilimumab: a case of takotsubo-like syndrome. J Immunother Cancer 2015; 3: 4.
65. Laubli H, Balmelli C, Bossard M, Pfister O et al. Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma. J Immunother Cancer 2015; 3: 11.
66. Martin-Liberal J, Furness AJ, Joshi K et al. Anti-programmed cell death-1 therapy and insulin-dependent diabetes: a case report. Cancer Immunol Immunother 2015; 64: 765–7.
67. Horneber M, Fischer I, Dimeo F et al. Cancer-related fatigue: epidemiology, pathogenesis, diagnosis, and treatment. Dtsch Arztebl Int 2012; 109: 161–71.
68. Downey SG, Klapper JA, Smith FO et al. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res 2007; 13: 6681–8.
69. Pavlov D, Marshall MA. Association of adverse events and tumor response in melanoma patients treated with tremelimumab. J Clin Oncol 2010; 28: abstract e13104.
70. Teulings HE, Limpens J, Jansen SN et al. Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis. J Clin Oncol 2015; 33: 773–81.
71. Sanlorenzo M, Vujic I, Daud A et al. Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression. JAMA Dermatol 2015; 151(11): 1206–12.